Uncategorized

Uncategorized

New Releases from NCBI BookshelfBlinatumomab (Blincyto): Indication: For the treatment of patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy: Reimbursement Recommendation [Internet].​Blinatumomab (Blincyto): Indication: For the treatment of patients with Philadelphia chromosome–negative, CD19-positive B-cell precursor acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy: Reimbursement Recommendation [Internet].

Canada’s Drug Agency (CDA-AMC) recommends that Blincyto be reimbursed by public drug plans for the treatment of patients with Philadelphia

Scroll to Top